Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2000

View Archived Issues

Protein-peptide fusion stimulates anticancer activity without adjuvant

Researchers identify ACE2, the first human homologue of ACE

Eptifibatide reduces death, myocardial infarction in unstable angina

Male osteoporosis treated effectively with alendronate in two-year study

Parkinson's marked by loss of norepinephrine nerve terminals in the heart

New proxifan H3 antagonist selected as development candidate for ADHD and Alzheimer's disease

Novel duocarmycin derivative suitable for use in anticancer immunoconjugates

Toleragen candidate for antibody-mediated thrombosis effective in preclinical model

Oleander extract selectively kills human cancer cells via an effect on TRF2

Rabeprazole superior to ranitidine in erosive gastroesophageal reflux disease

Antibody and protein therapeutics for breast cancer sought by Eos and Biogen collaboration

Update on U.S. status of Zonagen's sexual dysfunction products

Celgene expands product pipeline and technology platform with Signal acquisition

OSI's ERF receptor inhibitor continues to demonstrate anticancer activity and good safety

Important new approval obtained for Actos

Potent hydroxamate-based MMP-2 inhibitors disclosed by Abbott

Serine protease inhibitors for asthma, pancreatitis designed by Ortho-McNeil scientists

Series of patents covers American Cyanamid's new TACE inhibitors

Technetium complexes and their use in cardiac imaging

Novel treatments for obesity under study at Lilly

Pfizer prepares acid-stable, broad-spectrum macrolide antibiotics

HEV vaccine technology licensed to SmithKline Beecham

Encouraging results reported for phenserine in multiple-dose safety trial

Pfizer initiates clinical program for pagoclone

Phase I/II clinical trial demonstrates safety and tolerability of GVAX lung cancer vaccine

New therapy for AIDS wasting receives orphan product designation from E.C.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...